Company intelligence / Profile preview

TriviumVet

Waterford, Ireland

Ownership: Private
Development stage: Other

Overview

TriviumVet developed the first FDA-conditionally approved drug for feline hypertrophic cardiomyopathy—Felycin®‑CA1 (sirolimus delayed-release tablets)—and has a pipeline targeting major unmet needs in companion animal health including neuropathic pain, gastric ulcers, and chronic kidney disease. The company has received both FDA and EMA approvals/conditional approvals for several new animal drugs. It was acquired by PBI-Gordon Companies in May 2025.

Therapeutic areas: NephrologyGastroenterologyNeurologyCardiovascular
Modalities: Small moleculeDelayed-release formulationmTOR inhibitor platformProton pump inhibitor
Industry: Veterinary

Partnerships

Pegasus LaboratoriesPMBRC Technology Gateway

Beyond the preview

Go deeper on TriviumVet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TriviumVet.

Explore the full profile